Use of proton pump inhibitors correlates with increased risk of pancreatic cancer: a case-control study in Taiwan

ABSTRACT

To investigate whether use of proton pump inhibitors [PPIs] enhances the risk of pancreatic cancer. Retrospective case control study. Department of Public Health, China Medical University, Taiwan. We identified 977 patients aged 20 years or older with newly diagnosed pancreatic cancer as the case group between 2000 and 2010. The control group consisted of 3908 subjects without pancreatic cancer selected from the same sample. Use of Proton pump inhibitors. History of using PPIs and other comorbidities were compared between cases and controls. After adjustment for confounders, multivariable logistic regression analysis showed that pancreatic cancer had strong association with PPIs use [OR 9.28, 95% CI 7.77 - 11.08]. Among PPI drugs, those using esomeprazole were at the highest risk with an odds ratio of 12.1 [95% CI 9.76 - 15.0]. Taking PPIs correlates with increased risk of pancreatic cancer. The risk may greater for those taking esomeprazole